SOM Biotech Concludes 2020 with Advanced and Robust Pipeline
SOM Biotech, a biopharmaceutical company specialising in the repositioning of existing drugs for the treatment...
SOM0208 is a small molecule for the treatment of Niemann–Pick C disease.
Niemann–Pick type C is a lysosomal storage disorder caused by defects in the intracellular transport and metabolism of cholesterol and glycolipids. The disease has a broad clinical spectrum. Affected individuals may have enlargement of the spleen (splenomegaly) and liver (hepatomegaly), or enlarged spleen or liver combined (hepatosplenomegaly), but this finding may be absent in later onset cases. Prolonged jaundice or elevated bilirubin can present at birth.
SOM Biotech, a biopharmaceutical company specialising in the repositioning of existing drugs for the treatment...
The current Covid-19 pandemic situation has shown that repurposing drugs can be crucial for delivering...
SOM Biotech, a biopharmaceutical company specialising in the repositioning of existing drugs for the treatment...
SOM Biotech, a clinical-stage drug discovery and development company, announces the in vitro validation of...